Maersk to work with COVAXX to ship American Covid-19 vaccine
Maersk has signed an agreement with COVAXX to ship the Covid-19 vaccine from the American pharmaceutical company across the globe when and if regulatory authorities approve it.
COVAXX is currently conducting Phase 1 clinical trials of its vaccine in Taiwan and, upon regulatory approval, has an arrangement with the University of Nebraska Medical Center to perform Phase 2 trials in the U.S. The organization has advanced pre-commitments for more than 100 m doses around the world.
In September, COVAXX announced an agreement to perform a large-scale human efficacy clinical trial in South America's largest country with Dasa, the largest diagnostic medical company in Brazil.
To ensure successful transportation to developing countries, Maersk will oversee all logistics activities.
The agreement provides for the management, packaging and shipment of the end-to - end supply chain, by air or ocean, land transportation, warehouse storage and delivery to facilities to support COVAXX 's pharmaceutical grade, temperature-controlled supply chain requirements.
COVAXX plans to produce 100 million doses of its vaccine in early 2021, and one billion doses by the end of 2021.
Maritime Business World